Anti-Human IP-10 (CXCL10) 0 ReviewsSubmit a Review Product Details Catalog Number: 500-P93 Description: Source: Polyclonal Rabbit Preparation: Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIP-10. Anti-Human IP-10 specific antibody was purified by affinity chromatography employing immobilized hIP-10 matrix. Immunogen: E.coli derived Recombinant Human IP-10 (CXCL10) (PeproTech catalog# 300-12) Sandwich ELISA: To detect hIP-10 by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech’s Biotinylated Anti-Human IP-10 (500-P93Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIP-10. Western Blot: To detect hIP-10 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIP-10 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions. Note: Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information. Cross Reactivity Cited in References: Human, Mouse References SDS CoA Search Product Line Country Of Origin: USA Not for human use. Research Interest COVID-19 Angiogenesis/Cardiovascular Chemotaxis Immune System Inflammation Proliferation Wound Healing Allergy Transplantation Recent Citations First Author Mathieu, C Title Lethal Nipah virus infection induces rapid overexpression of CXCL10. Citation PLoS ONE; 7(2) pge32157 PubMed ID 22393386 First Author Rabquer, B J Title Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Citation Arthritis research & therapy; 13(1) pgR18 PubMed ID 21303517 First Author Izhak, L Title Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. Citation Journal of immunology (Baltimore, Md. : 1950); 184(2) pg1092-101 PubMed ID 19995900
